Terry-Ann Burrell Net Worth

The estimated Net Worth of Terry Ann Burrell is at least $8.54 Million dollars as of 1 April 2024. Ms. Burrell owns over 5,446 units of Beam Therapeutics stock worth over $1,691,704 and over the last 4 years she sold BEAM stock worth over $2,548,931. In addition, she makes $4,302,720 as Chief Financial Officer and Treasurer at Beam Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Burrell BEAM stock SEC Form 4 insiders trading

Terry has made over 10 trades of the Beam Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 5,446 units of BEAM stock worth $174,926 on 1 April 2024.

The largest trade she's ever made was selling 47,195 units of Beam Therapeutics stock on 18 January 2023 worth over $2,130,382. On average, Terry trades about 13,992 units every 81 days since 2020. As of 1 April 2024 she still owns at least 70,137 units of Beam Therapeutics stock.

You can see the complete history of Ms. Burrell stock trades at the bottom of the page.

Terry-Ann Burrell biography

Terry-Ann Burrell serves as Chief Financial Officer, Treasurer of the Company. From May 2008 to August 2019, Ms. Burrell worked at J.P. Morgan Securities LLC, where she most recently served as Managing Director. Ms. Burrell was responsible for deal execution across both mergers and acquisitions and capital markets. In her role, she advised biotechnology and pharmaceutical companies on strategic considerations, including mergers and acquisitions, initial public and secondary offerings and valuation analysis. Ms. Burrell holds a bachelor’s degree from Harvard College and an MBA from New York University’s Leonard N. Stern School of Business.

What is the salary of Terry Burrell?

As the Chief Financial Officer and Treasurer of Beam Therapeutics, the total compensation of Terry Burrell at Beam Therapeutics is $4,302,720. There are no executives at Beam Therapeutics getting paid more.

How old is Terry Burrell?

Terry Burrell is 42, she's been the Chief Financial Officer and Treasurer of Beam Therapeutics since 2019. There are 14 older and 1 younger executives at Beam Therapeutics. The oldest executive at Beam Therapeutics Inc. is Mark Fishman, 68, who is the Independent Director.

What's Terry Burrell's mailing address?

Terry's mailing address filed with the SEC is C/O BEAM THERAPEUTICS INC.,, 238 MAIN STREET, CAMBRIDGE, MA, 02142.

Insiders trading at Beam Therapeutics

Over the last 5 years, insiders at Beam Therapeutics have traded over $63,012,019 worth of Beam Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Llc Fmr, and Kristina Burow. On average, Beam Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $1,019,987. The most recent stock trade was executed by Amy Simon on 1 July 2024, trading 1,250 units of BEAM stock currently worth $29,100.

What does Beam Therapeutics do?

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Complete history of Ms. Burrell stock trades at Beam Therapeutics

Beam Therapeutics executives and stock owners

Beam Therapeutics executives and other stock owners filed with the SEC include:

• Terry-Ann Burrell,
  Chief Financial Officer, Treasurer
• John Evans,
  Chief Executive Officer, Director
• Giuseppe Ciaramella,
  President, Chief Scientific Officer
• John M. Evans M.B.A.,
  CEO & Director
• Dr. Giuseppe Ciaramella Ph.D.,
  Pres & Chief Scientific Officer
• Terry-Ann Burrell M.B.A.,
  CFO & Treasurer
• Carole Ho,
  Independent Director
• Mark Fishman,
  Independent Director
• Graham Cooper,
  Independent Director
• Robert Nelsen,
  Independent Director
• Stephen Knight,
  Independent Director
• Kristina Burow,
  Independent Director
• Christine Swenson,
  Senior Vice President - Regulatory Affairs
• Manmohan Singh,
  Senior Vice President - Pharmaceutical Sciences and Delivery Technology
• David Liu,
  Co-Founder
• J. Keith Joung,
  Co-Founder
• Dr. Alexis Komor Ph.D.,
  Co-Founder
• Dr. Nicole Gaudelli Ph.D.,
  Co-Founder
• Suzanne Fleming,
  Chief Accounting Officer
• Dr. J. Keith Joung M.D., Ph.D.,
  Co-Founder
• Courtney Wallace,
  Chief Bus. Officer
• Susan O'Connor,
  Chief HR Officer
• Dr. Christine P. Bellon J.D., Ph.D.,
  Sr. VP, Chief Legal Officer & Corp. Sec.
• Brian Riley,
  Sr. VP of Technical Operations
• Dr. Feng Zhang,
  Co-Founder
• John Maraganore,
  
• Kathleen E Walsh,
  
• Bethany J Cavanagh,
  SVP, Finance and Treasurer
• Group, Llc Green Jeremy Red...,
  
• Venture Partners Ix, Llcarc...,
  
• Venture Partners Ix, Llcarc...,
  
• Llc Fmr,
  
• Amy Simon,
  Chief Medical Officer
• Christine Bellon,
  Chief Legal Officer
• Christi Shaw,